(Q35819373)

10 August 2017

1 reference

title

Maximizing the clinical outcome with mTOR inhibitors in the renal transplant recipient: defining the role of calcineurin inhibitors (English)

1 reference

10 August 2017

Björn Nashan

1

1 reference

10 August 2017

publication date

22 June 2004

1 reference

10 August 2017

published in

Transplant International

1 reference

10 August 2017

volume

17

1 reference

10 August 2017

issue

6

1 reference

10 August 2017

page(s)

279-285

1 reference

Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00444.X

Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00444.X

A prospective, randomized clinical trial of cyclosporine reduction in stable patients greater than 12 months after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00444.X

SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00444.X

The in vivo effect of rapamycin derivative SDZ RAD on lymphocyte proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00444.X

Suppression of acute rejection in allogeneic rat lung transplantation: a study of the efficacy and pharmacokinetics of rapamycin derivative (SDZ RAD) used alone and in combination with a microemulsion formulation of cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00444.X

Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00444.X

Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00444.X

A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00444.X

Two-year results of multicenter phase III trials on the effect of the addition of sirolimus to Cyclosporine-based immunosuppressive regimens in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00444.X

Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00444.X

Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00444.X

Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00444.X

Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00444.X

Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00444.X

Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00444.X

Early clinical experience with a novel rapamycin derivative

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00444.X

Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00444.X

Rapamune® (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00444.X

Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00444.X

10.1111/J.1432-2277.2004.TB00444.X

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference